A Phase I, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of hCBE-11, a Humanized Monoclonal Antibody, in Subjects With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Monoclonal antibody CBE11 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Biogen
- 25 Apr 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 13 Oct 2005 New trial record.